Encouraging Activity in Poor-Risk Endometrial Cancer With HER2-Targeted Novel Drug

(MedPage Today) — SAN JUAN, PUERTO RICO — As many as 70% of patients with advanced/metastatic HER2-expressing endometrial cancer (EC) responded to an investigational antibody-drug conjugate (ADC), according to phase II data.
Response to trastuzumab…